BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 18029374)

  • 21. Triumph and tragedy: anemia management in chronic kidney disease.
    Novak JE; Szczech LA
    Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. L-carnitine supplementation in the dialysis population: are Australian patients missing out?
    Reuter SE; Faull RJ; Evans AM
    Nephrology (Carlton); 2008 Feb; 13(1):3-16. PubMed ID: 18199095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recommendations for the evaluation of hematologic response of dialysis patients.
    Desforges JF
    Kidney Int Suppl; 1975 Jan; (2):261-2. PubMed ID: 1057687
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of bleeding in dialysis patients.
    Galbusera M; Remuzzi G; Boccardo P
    Semin Dial; 2009; 22(3):279-86. PubMed ID: 19573008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vitamin C neglect in hemodialysis: sailing between Scylla and Charybdis.
    Handelman GJ
    Blood Purif; 2007; 25(1):58-61. PubMed ID: 17170539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comprehensive vision for intravenous iron therapy.
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comment on diagnosis and treatment of iron deficiency without anemia].
    Marko P
    Praxis (Bern 1994); 2010 Feb; 99(3):148; author reply 148. PubMed ID: 20127632
    [No Abstract]   [Full Text] [Related]  

  • 28. The importance and use of iron supplementation in uremia.
    Makoff R
    Nephrol News Issues; 1992 Jun; 6(6):14-6, 19. PubMed ID: 1608475
    [No Abstract]   [Full Text] [Related]  

  • 29. Endogenous plasma carnitine pool composition and response to erythropoietin treatment in chronic haemodialysis patients.
    Reuter SE; Faull RJ; Ranieri E; Evans AM
    Nephrol Dial Transplant; 2009 Mar; 24(3):990-6. PubMed ID: 18987259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Secondary oxalosis: a cause of delayed recovery of renal function in the setting of acute renal failure.
    Alkhunaizi AM; Chan L
    J Am Soc Nephrol; 1996 Nov; 7(11):2320-6. PubMed ID: 8959621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Route of administration for erythropoiesis-stimulating agents: patient and nursing considerations.
    Holloway M
    Nephrol Nurs J; 2007; 34(5):527-31. PubMed ID: 18041455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diet to reduce mild hyperoxaluria in patients with idiopathic calcium oxalate stone formation: a pilot study.
    Nouvenne A; Meschi T; Guerra A; Allegri F; Prati B; Fiaccadori E; Maggiore U; Borghi L
    Urology; 2009 Apr; 73(4):725-30, 730.e1. PubMed ID: 19193409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histidine supplements in the treatment of uraemic anaemia.
    Giordano C; De Santo NG; Rinaldi S; Acone D; Esposito R; Gallo B
    Proc Eur Dial Transplant Assoc; 1973; 10(0):160-5. PubMed ID: 4802497
    [No Abstract]   [Full Text] [Related]  

  • 34. Ascorbic acid depletion in chronic hemodialysis patients.
    Burge J; Park HS
    Mich Med; 1973 Aug; 72(24):533-4. PubMed ID: 4726738
    [No Abstract]   [Full Text] [Related]  

  • 35. Iron supplementation and oxidative stress in patients with uremia.
    Shetty JK; Prakash M
    Indian J Physiol Pharmacol; 2007; 51(2):179-82. PubMed ID: 18175664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical effects of oral fluoxymesterone in patients with dialysis-controlled uremia.
    Lindholm DD; Fisher JW; Vieira JA; Dombeck DH; Bernal G; Lerthora J
    Trans Am Soc Artif Intern Organs; 1973; 19():475-83. PubMed ID: 4722764
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of erythropoietin administration in uremia.
    Gurland HJ; Samtleben W; Schmidt B
    Contrib Nephrol; 1989; 70():172-7. PubMed ID: 2670428
    [No Abstract]   [Full Text] [Related]  

  • 38. Parenteral ascorbic acid in haemodialysis patients.
    Biesalski HK
    Curr Opin Clin Nutr Metab Care; 2008 Nov; 11(6):741-6. PubMed ID: 18827578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H; Mimura T; Honda N
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variations in hematocrit induced by hemodialysis.
    Di Iorio B; Bellizzi V
    Blood Purif; 2001; 19(1):68-9. PubMed ID: 11114580
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.